|
| related topics |
| {customer, product, revenue} |
| {product, liability, claim} |
| {product, market, service} |
| {property, intellectual, protect} |
| {personnel, key, retain} |
| {regulation, change, law} |
| {cost, contract, operation} |
| {operation, international, foreign} |
| {operation, natural, condition} |
| {provision, law, control} |
| {condition, economic, financial} |
|
|
OUR FUTURE GROWTH DEPENDS ON EXPANSION OF INTERNATIONAL REVENUES AND WE WILL BE SUBJECT TO INCREASED RISKS IN THE INTERNATIONAL MARKETPLACE
OUR FUTURE GROWTH ALSO DEPENDS ON THE DEVELOPMENT AND MARKET ACCEPTANCE OF NEW PRODUCTS
ECONOMIC FACTORS AFFECTING OUR CUSTOMERS MAY ADVERSELY AFFECT OUR FINANCIAL RESULTS
WE FACE RISKS OF COMPETITION AND CHANGING TECHNOLOGY
THE LOSS OF KEY CUSTOMERS COULD ADVERSELY AFFECT OUR FINANCIAL RESULTS
IF WE LOSE THE PROTECTION OF OUR PATENTS AND PROPRIETARY RIGHTS, OUR FINANCIAL RESULTS COULD SUFFER
Importance and Limitations of Patent and Proprietary Rights Protections
WE DO NOT MANUFACTURE MOST OF OUR DEVICES OR ANY OF OUR VACCINE PRODUCTS AND ARE DEPENDENT ON ONE CONTRACT MANUFACTURER FOR INOVOJECT AND EGG REMOVER DEVICES AND ANOTHER CONTRACT MANUFACTURER FOR AAC PRODUCTION. WE ARE ALSO DEPENDENT ON SINGLE CONTRACT MANUFACTURERS FOR PRODUCTION OF BOTH BURSAPLEX AND NEWPLEX
General Risks Associated with Reliance on Contract Manufacturers
Inovoject and Egg Remover Systems
WE FACE RISKS RELATED TO COMPLIANCE WITH LAWS IMPACTING CORPORATE GOVERNANCE AND FINANCIAL REPORTING STANDARDS
WE FACE THE RISK THAT WE MAY NEED TO MAKE ADDITIONAL CONTRIBUTIONS TO OUR 401(K) PLAN
POULTRY HEALTH AND DISEASE FACTORS AFFECTING OUR CUSTOMERS MAY ADVERSELY AFFECT OUR FINANCIAL RESULTS
WE ARE DEPENDENT ON DISTRIBUTORS IN CERTAIN MARKETS
THE LOSS OF KEY COLLABORATORS, SUPPLIERS AND OTHER KEY PARTIES COULD ADVERSELY AFFECT OUR FINANCIAL RESULTS
WE ARE SUBJECT TO AN INHERENT RISK OF PRODUCT LIABILITY
GOVERNMENT REGULATION AND THE NEED FOR REGULATORY APPROVAL MAY ADVERSELY AFFECT OUR BUSINESS
OUR INABILITY TO ATTRACT AND RETAIN KEY PERSONNEL COULD ADVERSELY AFFECT OUR BUSINESS
IF WE CANNOT CONTINUE TO PROVIDE TIMELY SUPPORT AND MAINTENANCE TO OUR CUSTOMERS, OUR BUSINESS MAY SUFFER
WE HAVE ANTI-TAKEOVER DEFENSES THAT COULD DISCOURAGE OR DELAY A TAKEOVER
Full 10-K form ▸
|
|
| related documents |
| 811240--3/17/2008--BIOLASE_TECHNOLOGY_INC |
| 57725--9/24/2010--LANNETT_CO_INC |
| 1069183--2/29/2008--TASER_INTERNATIONAL_INC |
| 868368--12/12/2008--ROCHESTER_MEDICAL_CORPORATION |
| 1014507--6/1/2006--SCHICK_TECHNOLOGIES_INC |
| 313927--2/24/2009--CHURCH_&_DWIGHT_CO_INC_/DE/ |
| 313927--2/24/2010--CHURCH_&_DWIGHT_CO_INC_/DE/ |
| 350907--3/16/2006--THORATEC_CORP |
| 1069183--3/15/2007--TASER_INTERNATIONAL_INC |
| 350907--2/27/2009--THORATEC_CORP |
| 1324759--3/31/2010--Cereplast_Inc |
| 1311538--6/29/2009--Castle_Brands_Inc |
| 350907--2/27/2008--THORATEC_CORP |
| 1013606--3/12/2007--ENDOLOGIX_INC_/DE/ |
| 1013606--3/16/2006--ENDOLOGIX_INC_/DE/ |
| 350907--4/2/2007--THORATEC_CORP |
| 18937--2/26/2008--CERADYNE_INC |
| 868368--12/26/2006--ROCHESTER_MEDICAL_CORPORATION |
| 868368--12/4/2007--ROCHESTER_MEDICAL_CORPORATION |
| 811240--3/19/2010--BIOLASE_TECHNOLOGY_INC |
| 868368--12/11/2009--ROCHESTER_MEDICAL_CORPORATION |
| 70793--12/11/2006--NBTY_INC |
| 868368--12/10/2010--ROCHESTER_MEDICAL_CORPORATION |
| 70793--11/27/2007--NBTY_INC |
| 874716--2/27/2008--IDEXX_LABORATORIES_INC_/DE |
| 884909--3/17/2008--HOME_DIAGNOSTICS_INC |
| 887708--6/14/2006--CARACO_PHARMACEUTICAL_LABORATORIES_LTD |
| 879682--3/28/2006--PLC_SYSTEMS_INC |
| 57725--9/29/2008--LANNETT_CO_INC |
| 891288--3/29/2007--QUESTCOR_PHARMACEUTICALS_INC |
|